Healthcare: After Spinning Off Its Fastest-Growing Drugs, What's Next For Biogen?

<p><strong>Competitors make headway against Teva Pharmaceutical's top-seller, and Biogen's hemophilia drugs become Bioverativ. Here's what you should know.</strong></p>